31/01/2023 17:16

Bubs Australia (BUB) 31.5c

BUB -11.27%: weaker China sales weighed on Bubs shares today, just a week after the stock rallied on the potential upside in China sales. Gross revenue in the quarter was down 28% on last year, weighed by a 66% slump in China sales, though international revenue climbed thanks to the emergency supply agreement signed with the US in the middle...

Read more

20/12/2022 09:37

Bubs Australia Ltd (BUB) 31c

If you had read the headlines about this infant formula business it would be easy to anticipate the stock trading higher after it gained US FDA approval in late 2021 plus revenue from China already appears to have turned but the stocks halved over the last few months i.e. a lack of guidance from the company back in August following their result clearly hasn’t helped.

Read more

30/08/2022 17:26

Bubs Australia (BUB) 57.5c

BUB -4.96%: a record year for Bubs after receiving a boost in sales on gaining US FDA approval late in the year. Revenue came in at $104m and underlying EBITDA of$4.8m were both ahead of guidance provided in July when the company raised $63m to scale up operations. Revenue from China bounced back, more than doubling vs FY21, as export...

Read more

30/08/2022 09:19

Bubs Australia Ltd (BUB) 60.5c

BUB had been enjoying strong growth in the Chinese baby formula market in similar fashion to A2M before Covid but over the last 2-years BUB has turned its attention more towards the US which is panning out strongly, although the company still enjoys 26% of its revenue from China sales. In July the company delivered a solid update and more financial data will be out this morning when they report FY22 results which should be helped tremendously by the US Governments emergency action to acquire much needed baby formula.

Read more

30/05/2022 17:06

Bubs Australia (BUB) 68c

BUB +40.21%: the infant formula company received FDA approval to sell tins into the US market today. America has been battling a shortage in infant formula after several brands were forced to recall products that had led to bacterial infections in a number of kids while supply chain issues have compounded the problem. As a result, the FDA fast-tracked the process to have seven of Bubs’ products available for sale...

Read more